Pure Global AI
NCT06382129Not yet recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
Sichuan Baili Pharmaceutical Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
BL-B01D1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
558 participants
Primary outcome

Overall survival (OS),Progression-free survival (PFS)

Summary

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate
 the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR
 wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies
 and platinum-based chemotherapy.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06382129
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06382129 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 558 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.